

Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape

Keity Souza Santos^{*1,2,3}, Jamille Ramos Oliveira^{1,2,3}, Rafael Rahal G. Machado⁴, Helen Andrade Arcuri⁵, Jhosiene Yukari Magawa^{1,2,3}, Isabela Pazotti Daher^{1,2,3}, Alysson Henrique Urbanski⁶, Gabriela Justamante Händel Schmitz^{1,2}, Roberto Carlos Vieira Silva Júnior², Edison Luiz Durigon⁴, Silvia Beatriz Boscardin^{7,2}, Daniela Santoro Rosa^{8,2}, Deborah Schechtman⁹, Helder I Nakaya^{6,10}, Edecio Cunha-Neto^{1,2,3}, Gabriele Gadermaier¹¹, Verônica Coelho^{1,2,3}, Jorge Kalil^{1,2,3} on behalf of COVID-19 SP-Brazil Team.

¹ Faculdade de Medicina da Universidade de São Paulo, Departamento de Clínica Médica, Disciplina de Alergia e Imunologia Clínica, São Paulo, SP, Brasil.

² Laboratório de Imunologia, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, (HCFMUSP) São Paulo da Universidade de São Paulo, SP, Brasil

³ Instituto de Investigação em Imunologia – Instituto Nacional de Ciências e Tecnologia – iii-INCT, Brasil

⁴ Instituto de Ciências Biomédicas, Departamento de Microbiologia, Universidade de São Paulo, São Paulo, SP, Brasil

⁵ Centro de Estudos de Insetos Sociais, Departamento de Biologia, Instituto de Biociências de Rio Claro, Universidade Estadual Paulista, Rio Claro, SP, Brasil.

⁶ Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brasil

⁷ Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil

⁸ Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, SP, Brasil.

⁹ Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brasil

¹⁰ Plataforma Científica Pasteur-USP, São Paulo, SP, Brasil

¹¹ Department of Biosciences, University of Salzburg, Salzburg, Austria

***Corresponding author:**

Laboratório de Imunologia, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, (HCFMUSP), Av. Dr. Enéas de Carvalho Aguiar, 44 - 90 - Bloco II, 05403-000, São Paulo, SP, Brazil.

Tel: +55(11) 2661-5907

E-mail: keity.santos@fm.usp.br

COVID-19 SP-Brazil Team in alphabetical order: Aline Martins, André Kenji Honda, Andreia Cristina Kazue Kuramoto Takara, Ariane Cesario Lima, Cesar Manuel Remuzgo Ruiz, Cesar Sato, Deibs Barbosa, Fernanda Romano Bruno, Edgar Ruz Fernandes, Giuliana Xavier De Medeiros, Greyce Luri Sasahara, João Paulo Silva Nunes, Juliana de Souza Apostolico Andrade, Lucas Caeu Jacintho, Luis Antonio Rodrigues Carneiro, Marco Antonio Stephano, Marcos Camargo Knirsch, Marcio Massao Yamamoto, Maria Lucia Carnevale Marin, Mirian Pinheiro Bruni, Rafael Ribeiro Almeida, Raquel Elaine de Alencar, Ricardo José Giordano, Roberta Liberato Pagni, Samar Freschi de Barros, Sandra Maria Monteiro, Simone Regina dos Santos.

SUPPORTING/ONLINE DISPLAY ITEMS

Supplementary Table S1 – Peptides immobilized in microarray.


Peptide #	amino acid sequence	SARS-CoV-2 RBD from Ancestral Wuhan Hu-1 isolate
P1	GSGSGSGCPFGEVFN	receptor binding domain
P2	GSGSGCPFGEVFNAT	receptor binding domain
P3	GSGCPFGEVFNATRF	receptor binding domain
P4	GCPFGEVFNATRFAS	receptor binding domain
P5	PFGEVFNATRFASVY	receptor binding domain
P6	GEVFNATRFASVYAW	receptor binding domain
P7	VFNATRFASVYAWNR	receptor binding domain
P8	NATRFASVYAWNRKR	receptor binding domain
P9	TRFASVYAWNRKRIS	receptor binding domain
P10	FASVYAWNRKRISNC	receptor binding domain
P11	SVYAWNKRISNCVA	receptor binding domain
P12	YAWNKRISNCVADY	receptor binding domain
P13	WNRKRISNCVADYSV	receptor binding domain
P14	RKRISNCVADYSVLY	receptor binding domain
P15	RISNCVADYSVLYNS	receptor binding domain
P16	SNCVADYSVLYNSAS	receptor binding domain
P17	CVADYSVLYNSASFS	receptor binding domain
P18	ADYSVLYNSASFSTF	receptor binding domain
P19	YSVLYNSASFSTFKC	receptor binding domain
P20	VLYNSASFSTFKCYG	receptor binding domain
P21	YNSASFSTFKCYGVS	receptor binding domain
P22	SASFSTFKCYGVSP	receptor binding domain
P23	SFSTFKCYGVSPPTKL	receptor binding domain
P24	STFKCYGVSPPTKLND	receptor binding domain
P25	FKCYGVSPPTKLNDLC	receptor binding domain
P26	CYGVSPPTKLNDLCFT	receptor binding domain
P27	GVSPTKLNDLCFTNV	receptor binding domain
P28	SPTKLNDLCFTNVYA	receptor binding domain
P29	TKLNDLCFTNVYADS	receptor binding domain
P30	LNDLCFTNVYADSFV	receptor binding domain
P31	DLCFTNVYADSFVIR	receptor binding domain
P32	CFTNVYADSFVIRGD	receptor binding domain
P33	TNVYADSFVIRGDEV	receptor binding domain
P34	VYADSFVIRGDEVRQ	receptor binding domain
P35	ADSFVIRGDEVRQIA	receptor binding domain
P36	SFVIRGDEVRQIAPG	receptor binding domain
P37	VIRGDEVRQIAPGQT	receptor binding domain

P38	RGDEVRQIAPGQTGK	receptor binding domain
P39	DEVRQIAPGQTG KIA	receptor binding domain
P40	VRQIAPGQTG KIADY	receptor binding domain
P41	QIAPGQTG KIADYNY	receptor binding domain
P42	APGQTG KIADYNYKL	receptor binding domain
P43	GQTG KIADYNYKLPD	receptor binding domain
P44	TG KIADYNYKLPDDF	receptor binding domain
P45	KIADYNYKLPDDFTG	receptor binding domain
P46	ADYNYKLPDDFTGCV	receptor binding domain
P47	YNYKLPDDFTGCVIA	receptor binding domain
P48	YKLPDDFTGCVIAWN	receptor binding domain
P49	LPDDFTGCVIAWNSN	receptor binding domain
P50	DDFTGCVIAWNSNNL	receptor binding domain
P51	FTGCVIAWNSNNLDS	receptor binding domain
P52	GCVIAWNSNNLDSKV	receptor binding domain
P53	VIAWNSNNLDSKVGG	receptor binding domain
P54	AWNSNNLDSKVGGNY	receptor binding domain
P55	NSNNLDSKVGGNYNY	receptor binding domain
P56	NNLDSKVGGNYNYLY	receptor binding domain
P57	LDSKVGGNYNYLYRL	receptor binding domain
P58	SKVGGNYNYLYRLFR	receptor binding domain
P59	VGGNYNYLYRLFRKS	receptor binding domain
P60	GNYNLYYRLFRKSNL	receptor binding domain
P61	YNLYYRLFRKSNLKP	receptor binding domain
P62	YLYRLFRKSNLKPFE	receptor binding domain
P63	YRLFRKSNLKFPERD	receptor binding domain
P64	LFRKSNLKFPERDIS	receptor binding domain
P65	RKSNLKFPERDISTE	receptor binding domain
P66	SNLKFPERDISTEIY	receptor binding domain
P67	LKFPERDISTEIYQA	receptor binding domain
P68	PFERDISTEIYQAGS	receptor binding domain
P69	ERDISTEIYQAGSTP	receptor binding domain
P70	DISTEIYQAGSTPCN	receptor binding domain
P71	STEIYQAGSTPCNGV	receptor binding domain
P72	EIYQAGSTPCNGVEG	receptor binding domain
P73	YQAGSTPCNGVEGFN	receptor binding domain
P74	AGSTPCNGVEGFNCY	receptor binding domain
P75	STPCNGVEGFNCYFP	receptor binding domain
P76	PCNGVEGFNCYFPLQ	receptor binding domain
P77	NGVEGFNCYFPLQSY	receptor binding domain
P78	VEGFNCYFPLQSYGF	receptor binding domain
P79	GFNCYFPLQSYGFQP	receptor binding domain
P80	NCYFPLQSYGFQPTN	receptor binding domain


P81	YFPLQSYGFQPTNGV	receptor binding domain
P82	PLQSYGFQPTNGVGY	receptor binding domain
P83	QSYGFQPTNGVGYQP	receptor binding domain
P84	YGFQPTNGVGYQPYR	receptor binding domain
P85	FQPTNGVGYQPYRVV	receptor binding domain
P86	PTNGVGYQPYRVVVL	receptor binding domain
P87	NGVGYQPYRVVVL	receptor binding domain
P88	VGYQPYRVVVL	receptor binding domain
P89	YQPYRVVVL	receptor binding domain
P90	PYRVVVL	receptor binding domain
P91	RVVVVL	receptor binding domain

color code

orange	strong reactivity with only IgG
blue	strong reactivity with only IgA
violet	strong reactivity with both IgG and IgA



Supplementary Figure S1. Percentage of individuals grouped according to high ($\geq 1:160$ VNT) or low neutralization ($< 1:160$ VNT) capacity (n=71).



Supplementary Figure S2. Differential IgG and IgA mean fluorescence intensity of reactivity to selected RBD peptides comparing individuals with high or low neutralization capacities. High N: individuals with high neutralization capacity ($\geq 1:160$ virus neutralization titer); Low N: individuals with low neutralization capacity ($< 1:160$ virus neutralization titer); MFI: mean fluorescence intensity; the median is shown as a solid line, the box indicates the 25th and 75th percentiles, whiskers range from the highest to the lowest value (all data points shown).